8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

| Indication                        | Rhabdomyosarcoma primary site
| INN                               | Vincristine
| Medicine type                     | Chemical agent
| List type                         | Complementary (EML) (EMLc)
| Formulations                      | Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
| EML status history                | First added in 2015 (TRS 994)
|                                   | Changed in 2021 (TRS 1035)
| Sex                               | All
| Age                               | Also recommended for children
| Therapeutic alternatives          | The recommendation is for this specific medicine
| Patent information                | Patents have expired in most jurisdictions
|                                   | Read more about patents.
| Tags                              | Cancer
| Wikipedia                         | Vincristine
| DrugBank                          | Vincristine

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1 mg/mL and 2 mg/2 mL) to the EML and EMLc.